Bausch + Lomb (BLCO) to Release Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is scheduled to be announcing its earnings results before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of $0.16 per share for the quarter. Bausch + Lomb has set its FY 2024 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.13 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.13. Bausch + Lomb had a negative net margin of 10.15% and a positive return on equity of 3.36%. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the company posted $0.18 EPS. Bausch + Lomb’s revenue was up 17.5% on a year-over-year basis. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bausch + Lomb Trading Down 0.4 %

Shares of NYSE BLCO opened at $20.37 on Tuesday. Bausch + Lomb has a 1 year low of $13.16 and a 1 year high of $21.69. The stock has a market cap of $7.17 billion, a P/E ratio of -21.22, a price-to-earnings-growth ratio of 1.76 and a beta of 0.48. The firm has a 50-day moving average of $18.26 and a 200 day moving average of $16.31. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.65 and a quick ratio of 1.01.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Stifel Nicolaus raised their price objective on shares of Bausch + Lomb from $16.00 to $19.00 and gave the company a “hold” rating in a research note on Monday, September 23rd. Royal Bank of Canada raised their price objective on shares of Bausch + Lomb from $20.00 to $23.00 and gave the company an “outperform” rating in a research note on Tuesday, October 22nd. Evercore ISI upgraded shares of Bausch + Lomb from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $19.00 to $25.00 in a research note on Tuesday, October 15th. HC Wainwright raised their price objective on shares of Bausch + Lomb from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Bausch + Lomb in a research note on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $20.27.

Insider Transactions at Bausch + Lomb

In related news, CEO Brent L. Saunders purchased 32,250 shares of Bausch + Lomb stock in a transaction dated Monday, August 5th. The stock was purchased at an average cost of $15.66 per share, for a total transaction of $505,035.00. Following the completion of the purchase, the chief executive officer now directly owns 595,169 shares of the company’s stock, valued at $9,320,346.54. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.15% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.